Amylin’s Byetta Records $7.5 Mil. In Sales Following June Launch
This article was originally published in The Pink Sheet Daily
Market uptake for the product could be stronger than Rx tracking numbers show due to strength in mail-order prescriptions, the company said.
You may also be interested in...
Amylin will put 325 reps behind exenatide, in addition to a Lilly sales force. The firms will target 60,000 physicians in first six months. First-in-class gut hormone follows approval of Amylin’s diabetes therapy Symlin in March.
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles